The boom of copyright’s drug initially drove significant expansion in the drug sector, generating a perception of easy gains. However, funding in companies heavily reliant on blockbuster drugs like Sildenafil presents significant dangers. Intellectual property end has caused generic rivalry, decreasing revenue portion and possibly diminishing exp

The recent surge in capital into boutique pharmaceutical companies, particularly those focusing on experimental therapies and complex drug development programs, has fueled what some are calling "High Roller Pharma." While the potential for revolutionary treatments and impressive returns is certain, the associated risks are also notable. Many of the